Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.70 |
| ▸ | CPA3 | P15088 | 3/20 | 0.68 |
| ▸ | FOLH1 | Q04609 | 2/20 | 0.64 |
| ▸ | CPA1 | P15085 | 7/20 | 0.61 |
| ▸ | CPB1 | P15086 | 1/20 | 0.61 |
| ▸ | CPB2 | Q96IY4 | 1/20 | 0.61 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.56 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.56 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.56 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.56 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.56 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.56 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.56 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.56 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.56 |
| ▸ | AKR1A1 | P14550 | 1/20 | 0.56 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.56 |
| ▸ | HTR2A | P28223 | 1/20 | 0.56 |
| ▸ | HTR2C | P28335 | 1/20 | 0.56 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6657008 | 1.00 | CYP1A2 (0.70) | CYP1A2CPA3FOLH1CPA1CPB1 | |
| SCHEMBL12494702 | 0.96 | CYP1A2 (0.66) | CYP1A2CPA3FOLH1CPA1CPB1 | |
| SCHEMBL12494942 | 0.96 | CYP1A2 (0.66) | CYP1A2CPA3FOLH1CPA1CPB1 | |
| SCHEMBL7300579 | 0.89 | FOLH1 (0.70) | CYP1A2CPA3FOLH1CPA1CPB1 | |
| SCHEMBL5710051 | 0.89 | CYP1A2 (0.59) | CYP1A2CPA3FOLH1CPA1CPB1 | |
| SCHEMBL12494233 | 0.88 | CYP1A2 (0.83) | CYP1A2CPA3FOLH1CPA1CPB1 | |
| SCHEMBL19821208 | 0.88 | CYP1A2 (0.83) | CYP1A2CPA3FOLH1CPA1CPB1 | |
| SCHEMBL6724759 | 0.88 | CYP1A2 (0.83) | CYP1A2CPA3FOLH1CPA1CPB1 | |
| SCHEMBL10778624 | 0.87 | FOLH1 (0.68) | CYP1A2CPA3FOLH1CPA1CPB1 | |
| SCHEMBL27513375 | 0.87 | FOLH1 (0.68) | CYP1A2CPA3FOLH1CPA1CPB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2529277-B1 | FLEXOGRAPHIC PROCESSING SOLUTION AND USE | EASTMAN KODAK CO (US) | 2019-04-03 | — | — | EP | claimed |
| US-20050267168-A1 | Pentanoic acid derivatives | ONO PHARMACEUTICAL CO., LTD. | 2005-12-01 | — | — | US | claimed |
| CN-1200703-C | Use of pentanoate derivant | ONO PHARMACEUTICAL CO (JP) | 2005-05-11 | — | — | CN | claimed |
| US-20030096802-A1 | Pentanoic acid derivatives | ONO PHARMACEUTICAL CO., LTD. | 2003-05-22 | — | — | US | claimed |
| US-RE37670-E1 | Antiproliferative and neurotrophic molecules | AMERICAN BIOGENETICS INC. | 2002-04-23 | — | — | US | claimed |
| CN-1322524-A | Use of pentanoate derivant | ONO PHARMACEUTICAL CO (JP) | 2001-11-21 | — | — | CN | claimed |
| US-6201021-B1 | TREATMENT OF DISEASES INDUCED BY REACTIVE ASTROCYTES | ONO PHARMACEUTICAL CO., LTD. (JP) | 2001-03-13 | — | — | US | claimed |
| EP-0632008-B1 | Pentanoic acid derivatives | ONO PHARMACEUTICAL CO (JP) | 1998-02-04 | — | — | EP | claimed |
| US-5672746-A | UNSATURATED ALKYL CARBOXYLIC ACIDS(AND THEIR SALTS) FOR TREATMENT OR PREVENTION OF NERVOUS SYSTEM DISORDERS | AMERICAN BIOGENETIC SCIENCES, INC. (US) | 1997-09-30 | — | — | US | claimed |
| EP-0632008-A1 | Pentanoic acid derivatives | ONO PHARMACEUTICAL CO., LTD. (JP) | 1995-01-04 | — | — | EP | claimed |
| US-20250231157-A1 | METHOD FOR DETERMINING THE PARTITION OF NAPHTHENIC ACIDS FROM A PRODUCTION WATER MIMICKING SYSTEM AND MIMICKING SYSTEM | PETRÓLEO BRASILEIRO S.A. – PETROBRAS (BR) | 2025-07-17 | — | — | US | disclosed |
| CN-104619327-B | Prodrug as the amido quinazoline of kinase inhibitor | 葛兰素史密斯克莱知识产权发展有限公司 | 2017-03-08 | — | — | CN | disclosed |
| WO-2015134467-A1 | METHODS AND COMPOSITIONS FOR DIRECT RADIOACTIVE LABELING OF BIO-ACTIVE MOLECULES AND BUILDING BLOCKS | THE TRUSTEES OF PRINCETON UNIVERSITY (US) | 2015-09-11 | — | — | WO | disclosed |
| US-8569058-B2 | Nerve regeneration promoters | ONO PHARMACEUTICAL CO., LTD. (JP) | 2013-10-29 | — | — | US | disclosed |
| EP-2094662-A1 | POLYCYCLIC ACID COMPOUNDS USEFUL AS CRTH2 ANTAGONISTS AND ANTIALLERGIC AGENTS | Astellas Pharma Inc. (JP) | 2009-09-02 | — | — | EP | disclosed |
| EP-0686155-A1 | XANTHINE DERIVATIVES AS ADENOSINE A1 RECEPTOR ANTAGONISTS | MERRELL PHARMACEUTICALS INC. (US) | 1995-12-13 | — | — | EP | disclosed |
| WO-1994019349-A1 | XANTHINE DERIVATIVES AS ADENOSINE A1 RECEPTOR ANTAGONISTS | MERRELL DOW PHARMACEUTICALS INC. (US) | 1994-09-01 | — | — | WO | disclosed |
| CN-1055181-A | SELECTIVE ADENOSINE RECEPTOR AGENTS | MERRELL DOW PHARMA (US) | 1991-10-09 | — | — | CN | disclosed |
| EP-0449175-A2 | Selective adenosine receptor agents | MERRELL PHARMACEUTICALS INC. (US) | 1991-10-02 | — | — | EP | disclosed |
| US-5047534-A | Xanthine derivatives; hyupotensive agents, cardiotonic agents | MERRELL DOW PHARMACEUTICALS INC. (US) | 1991-09-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050267168-A1 | Pentanoic acid derivatives | FFAR3, FFAR1, HCAR3 | CYP1A2 3287/4885CPA3 1989/4885FOLH1 3110/4885 |
| US-20030096802-A1 | Pentanoic acid derivatives | FFAR3, FPR1, FPR3 | CYP1A2 3377/4885CPA3 1028/4885FOLH1 2384/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.